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Abstract 
 
Background: Premature neonates are at risk for severe anemia and erythropoietin is the most important hor-
mone in erythropoiesis. The aim of this study was to evaluate the influence of oral recombinant human erythro-
poietin (rhEPO) in proving erythropoiesis in neonates. 
 
Methods: This was a randomized clinical trial study. Thirty neonates were enrolled from September 2007 to 
September 2008. The first group received oral rhEPO and Fe and the second, subcutaneous rhEPO and Fe. The 
patients’ Hb, HCT and the need to blood transfusion were recorded. We included all infants with gestational age 
<34 weeks, birth weight <1500 gr, without respiratory distress (O2 Saturation> 85%, FiO2 of 30%), full feeding 
tolerance so that oral Fe can be administrated.  
 
Results: In first group (oral=PO), 65% of neonates were female and 35% were male, mean weight was 1140 g 
and mean GA was 32.6 weeks. In the second group (subcutaneous=SC), 42% were female and 58% were male. 
The mean weight was 1245 g and mean GA was 31.2 weeks and this was not statistically significant. In the first 
group, the mean Hb and HCT were 9.7±1.9 and 29.6±5.9 g/dl. In the second group, the figures were 12.5±1.7 
and 38.8±5.1 which were statistically significant. There was no difference in the weight gain between two groups. 
In the first group, 3 neonates (20%) and in the second one, 1 neonate (15%) needed blood transfusion. 
 
Conclusions: rhEPO administration either PO or SC could prevent anemia of prematurity but SC rout was more 
effective. 
 
Keywords: Anemia; Prematurity; Recombinant erythropoietin; Newborn 
 
 
Introduction 
 
Anemia in neonates is defined as more than 2 SD un-
der the mean value of the amount of hemoglobin or 
HCT for a given age.
1 Anemia of prematurity starts at 
third or fourth week after birth and the amount of Hb 
may decrease to 7 g/dl.
2 It sometimes has clinical 
manifestations like pallor, apnea, no weight gain, de-
crease in activity, tachypnea, tachycardia and nutri-
tional problems that necessitates blood transfusion.
1,2 
On the other hand, recombinant human EPO 
(rhEPO) is the major factor in erythropoiesis in the fetal 
and neonatal period as well as in puberty by inhibition 
of apoptosis of progenitors in erythroid lineage and pro-
voking their proliferation and differentiation to normo-
blasts.
3 Another benefit of rhEPO is the protective effect 
against ischemic encephalopathy in neonates.
4 
The use of rhEPO for treatment of anemia goes 
back to1985.
5 Serum level of rhEPO in premature 
neonates is lower than mature neonates and after birth 
its level decreases even more.
6 This is one cause of 
blood transfusion in premature infants.
2 It is known 
that rhEPO does not cross the placenta. Jull et al. has 
observed that rhEPO found in mother's milk is pro-
duced by mammary glands and is secreted into milk.
5 
It has been observed that the level of  rhEPO is added 
to mother's milk as standard formula milk under   
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conditions similar to that of the stomach or intestine 
remaining constant, but rhEPO added to 5% dextrose 
serum, undergoes digestion.
7 
Erythropoietin has many properties and its recep-
tors are found on liver, endothelial, smooth muscle, 
placenta, brain and testis cells as well as on cardio-
myocytes and erythrocytes. 
We know that blood brain barrier and blood testis 
barrier prevent the passage of this hormone; it is possi-
ble that rhEPO is synthesized in these organs for rea-
sons other than erythropoises.
8-11  Since 1985, when 
rhEPO was available in market, it was used in the pre-
vention and the treatment of anemia of prematurity. It 
has some side effects that were reported in neonates.
10 
According to Ahmadpoor et al. study, rhEPO can 
decrease incidence of anemia of prematurity and its 
complications. In Ballin’s study, 6 premature neo-
nates received only Fe drops and 6 other neonates 
were administered Fe drops and rhEPO. 
In the rhEPO group, no complication was reported 
and serum level of rhEPO and reticulocyte number in-
creased significantly. Ferritin level decreased, but the 
need for transfusion did not decrease.
1 Although it has 
been approved that rhEPO plays a role in the prevention 
of prematurity anemia, but in most clinical trials, rhEPO 
was administrated intravenously or subcutaneously (IV, 
SQ). Few studies were carried out to determine the ef-
fectiveness of rhEPO in prevention of prematurity ane-
mia and even they had controversial results. 
In this study, we compared the effect of oral 
rhEPO with subcutaneous rhEPO and investigate its 
effectiveness in prevention of anemia of prematurity. 
We have evaluated a simple and more suitable way 
for prevention of anemia of prematurity. 
 
 
Materials and Methods 
 
This study is a randomized clinical trial, in which 30 
neonates having the qualifications of the study, were 
studied from first September 2007 to 1st September 
2008 in Quaem Hospital in Mashhad (Iran). During a 
period of one year, 30 premature neonates, having an 
age of less than 34 weeks and a weight under 1.5 kg 
and were hospitalized in the hospital were randomly 
divided into two groups.  
The first group was given oral rhEPO and oral Fe 
(rhEPO: 400 u/kg per weeks, Fe: 4 mg/kg/day). 
RhEPO was given during the first week after birth 
and at the beginning of the trials as well as in the 2
nd 
and 4
th week, the level of HCT, Hb and reticulocytes 
was checked. 
Also weight gain, the need to blood transfusion 
and other information related to this study were rec-
orded by a researcher daily. Other information was 
recorded using a questionnaire. The inclusion criteria 
in the study comprised all infants with gestational age 
less than 34 weeks, birth weight less than 1500 gr, 
absence of respiratory distress (O2 saturation> 85% 
with FiO2 of 30%), and full feeding tolerance so that 
oral Fe can be administrated. 
Also we excluded all neonates with acquired or 
congenital infections, intracranial hemorrhage, vomit-
ing or diarrhea, malabsorption, another types of ane-
mia (ABO incompatibility and G6PD deficiency), or 
life threatening anomalies. The sample size was cal-
culated according to 80% powers and 95% confi-
dence. Seven neonates were allocated for each group. 
A written consent form was taken from both parents.  
The results in the 2 groups were compared and ana-
lyzed with SPSS software (Version11.5, Chicago, IL, 
USA) and t-paired and repeated measurement tests. 
 
 
Results  
 
Thirty subjects were enrolled in the study. The aver-
age  birth weight  of neonates in the first group was 
1632±313 g and in the second group was 1826±399 
g.The weight gaining pattern in the two groups did 
not have any significant difference (p=0.151). Ac-
cording to Table 1 in every group, Hb level at birth 
and day 28, a significant difference was observed 
(p<0.001). A significant difference in Hb level be-
tween the 2 groups was noticed (p<0.001) (Table 1). 
The patients receiving blood were excluded. A 
significant difference (p<0.001) regarding Hb level 
and repeated measurement test, the level of HCT at 
Table 1: Mean of Hb at the birth day and 28
th day. 
All 
 
Oral rEPO
Mean±SD 
Subcutaneous rEPO
Mean±SD 
 
2.6±14.2  2.5±13.2  14.1±1.7  Birth day 
2.3±11.1  1.9±9.7  12.5±1.7  28
th day 
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the birth day and day 28 showed a significant differ-
ence (p<0.001) regarding the 2 groups (Table 2). 
After excluding the patients who received blood , 
the results showed a significant differences again and 
after omitting the recipients of blood, no significant 
difference was observed (p=0.412) (Table 3).  
 
 
Discussion 
 
In this study, EPO administration either orally or sub-
cutaneously prevented prematurity anemia in the 4
th 
week, but better results were obtained in the subcuta-
neous EPO group. In Ohls’s study, treatment with 
oral and IV EPO was effective in preventing the de-
crease of Hb and HCT to the level of anemia of 
prematurity (<7 mg/dl) so that neither groups had a 
Hb less than 7 g/dL in the 4
th week after birth.
12 
In the oral EPO group, average of Hb in 4
th week 
was 9.7±1.9 g/dL in the IV EPO group, which shows 
a significant statistical difference (p<0.001). However 
we can say that IV EPO was more effective than the 
oral form. If we notice that in the oral rhEPO group, 
the Hb level was less than the IV group, we can say 
that" It is probable that oral rhEPO is as effective as 
IV rhEPO since the fall in Hb in the two groups in 4
th 
week did not have much difference. 
In our study, similar amount of blood was with-
drawn from the two groups before and during the in-
vestigation period, but the need for transfusion in the 
oral rhEPO group was more. We performed blood 
transfusion on 3 neonates of the oral rhEPO group 
(20%) and one neonate in the subcutaneous rhEPO 
group (6%). 
On the other hand, according to various studies 
showing that 50% of neonates had birth weight less 
than 500 g, there was a need for multiple transfusions 
of packed cells. So oral and subcutaneous rhEPO 
were effective in decreasing the need for blood trans-
fusion.
3 In a prospective study in which 6 neonates 
did not receive rhEPO, it was shown that rhEPO 
could not increase erythropoiesis.
1 
Ballin et al. showed that rhEPO mixed with milk 
and administrated orally could increase erythropoesis 
in premature neonates. Serum erythropoietin level 
and reticulocytes could increase the level of ferritin 
which shows that Fe stores were depleted in order to 
be used in Hb synthesis.
1 
Similar results were obtained in our study as in the 
oral rhEPO group, the Hb level at birth and 4
th weeks 
after treatment showed a significant difference. Of 
course, serum erythropoietin level and reticulocyte 
count were not obtained in our study.  Britten et al. 
reported that in 6 neonates who received 1000 u/kg 
oral rhEPO for 10 days, high levels of serum rhEPO 
two hours after administrating the drug were recog-
nized. Although oral rhEPO increased erythropoesis, 
but the need to packed cell transfusion did not de-
crease.
3 These results matches with our results since 
in our study 3 out of 15 neonates needed packed cell 
transfusion. A retrospective study was conducted by 
Ledbetter in order to study the effect of rhEPO on 
human GI system.
9 
Neonates having a 1250 g birth weight and admit-
Table 2: Mean of HCT at the birth day and 28
th day.
All  Oral rEPO
Mean±SD 
Subcutaneous rEPO
Mean±SD 
 
42.1±7  39±6.4  45.2±6.5  Birth day 
34.2±7.2  29.6±5.9  38.8±5.1  28
th day 
 
 
Table 3: Mean of weight gaining in 2 groups in difference days. 
Birthday Oral  rEPO   
Mean±SD 
Subcutaneous rEPO 
Mean±SD 
All P value
3
th Day 186±1140  163±1245  180±1193  0.110 
7
th Day  237±1201  190±1304  217±1253  0.211 
10
th Day  212±1248  283±1370  249±1302  0.202 
14
th Day  196±1276  331±1472  282±1370  0.071 
17
th Day  297±1355  349±1584  338±1465  0.071 
21
th Day  309±1428  360±1680  344±1580  0.170 
24
th Day  296±1540  372±1759  347±1644  0.121 
28
th Day  313±1632  399±1826  365±1729  0.151 
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ted to their NICU between the years 1993 and 1997, 
and 260 neonates received rhEPO and another 233 
neonates were allocated as a control group. The inci-
dence of NEC following treatment decreased (4.61% 
compared to 10.76%, p<0.05). 
Gestational age in treated neonates was less than 
control group (26.8±2.1 compared to 27.6 ±2.9 
weeks, p<0.05). Birth weight, APGAR of 1
st minute 
and gender prevalence were not different in 2 groups. 
It was shown that in premature neonates with 500-
1250 g birth weight, the incidence of NEC in the 
rhEPO receiving group was less. Feeding intolerance 
(residue increase) and vomiting were not observed in 
neonates receiving oral rhEPO.
9  Although in our 
study the effects on GI system were not investigated 
but in this study orally EPO prevented prematurity 
anemia. In this investigation, it was shown that 
rhEPO administration (400 u/kg) either orally or sub-
cutaneously in the 4
th week of birth prevented the in-
cidence of prematurity anemia. However, better re-
sults were obtained in the subcutaneous EPO group. 
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